Sanofi: Depression trials
The registry lists 22 Depression studies with Sanofi as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 2 3Phase 3 18Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive DisorderCompletedNCT00855530Phase 3
- Efficacy and Safety of SR58611 Compared to Placebo and ParoxetineCompletedNCT00825058Phase 3
- Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and ParoxetineCompletedNCT00825019Phase 3
- An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly PatientsCompletedNCT00822744Phase 2
- An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive DisorderCompletedNCT00629551Phase 3
- An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive DisorderCompletedNCT00531622Phase 3
- A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With DepressionCompletedNCT00429260Phase 3
- An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive DisorderCompletedNCT00415142Phase 3
- Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)CompletedNCT00385307Phase 3
- An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive DisorderCompletedNCT00361491Phase 2
- An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive DisorderCompletedNCT00358631Phase 2
- A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive DisorderCompletedNCT00345098Phase 3
- A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)CompletedNCT00336713Phase 3
- An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With DepressionCompletedNCT00319709Phase 3
- STILDEP: Zolpidem in Depressive and Dysthimic PatientsCompletedNCT00292734Phase 4
- An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionCompletedNCT00256113Phase 3
- Efficacy and Safety of SR58611A in Patients With Major Depressive DisorderCompletedNCT00252356Phase 3
- Efficacy and Safety of SR58611A in Patients With Major Depressive DisorderCompletedNCT00252330Phase 3
- A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With DepressionCompletedNCT00250653Phase 3
- An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionCompletedNCT00250627Phase 3
- An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionCompletedNCT00250614Phase 3
- An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionCompletedNCT00250601Phase 3